Navigation Links
Coronado Biosciences Closes $25.8M in Series C Financing
Date:7/6/2011

NEW YORK, July 6, 2011 /PRNewswire/ -- Coronado Biosciences, a biopharmaceutical company focused on novel immunotherapy agents for inflammatory diseases and cancer, today announced that it closed a $25.8 million Series C financing led by National Securities Corporation.

Coronado plans to use the proceeds from the financing to advance its pipeline, including funding a Phase II study of the company's lead development candidate, CNDO-201 for the treatment of Crohn's Disease and a Phase I/II study of CNDO-109 for the treatment of relapsed Acute Myeloid Leukemia (AML).  Each of these drugs is a novel therapy that has achieved clinical proof-of-concept in indications with unmet medical needs. CNDO-201 is also in development for other autoimmune diseases, including ulcerative colitis and multiple sclerosis.

CNDO-201 (Trichuris suis ova) is a novel, orally administered, natural immunomodulator that regulates T-Cells and inflammatory cytokines.  The use of porcine whipworm ova represents a novel approach and mechanism of action to treating autoimmune diseases that is based on the "hygiene hypothesis."  CNDO-201 has demonstrated meaningful clinical activity and a good safety profile in a three independent investigator sponsored clinical trials.  A Company sponsored Phase II double-blind, placebo controlled trial of CNDO-201 for the treatment of Crohn's Disease is scheduled for initiation in early 2012.  

CNDO-109 is a novel anti-cancer drug that primes natural killer (NK) cells without the need for cytokine (IL-2) treatment and shows significant potential for the treatment of hematological and solid tumors. CNDO-109 has produced impressive results in a Phase I clinical trial in patients with AML and demonstrated preclinical activity in multiple myeloma, breast cancer, prostate cancer and ovarian cancer.  Coronado plans to initiate a Phase I/II dose escalation and expansion trial in patients with relapsed AML in 2012.  

About Coronado Biosciences

Coronado BioSciences is a biopharmaceutical company focused on novel immunotherapy agents for inflammatory diseases and cancer that target major unmet clinical needs in autoimmune disease and cancer.  Founded in 2006, Coronado is based in New York, NY. For more information, please visit www.coronadobiosciences.com.

Contact Information:
Investor Relations
Marcy Nanus, Vice President
The Trout Group, LLC.
646-378-2927; mnanus@troutgroup.com

Media Relations
Dennis S. Dobson Jr., CEO
Dobson Media Group
203-258-0159


'/>"/>
SOURCE Coronado Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
2. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
3. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
4. Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis
5. Generex Announces Intention to Dividend a Portion of Anticipated Amarantus BioSciences Shares to Its Shareholders upon a Reverse Stock Split
6. Neurocrine Biosciences to Present at the Jefferies 2011 Global Healthcare Conference
7. Generex in Agreement to License RapidMist™ Technology for $10 Million to Amarantus BioSciences for Use With Its Proprietary MANF Proteins
8. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
9. Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics®
10. BD Biosciences Launches New Cell Analyzer to Streamline Research Workflow
11. Cell Biosciences Acquires Brightwell Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
(Date:4/19/2017)... 19, 2017 Companion ... response in pets such as canine, avian and ... various types such as Attenuated Live Vaccines, Conjugate ... Vaccines and Recombinant Vaccines. Attenuated live vaccines are ... bacteria, which have been weakend under laboratory conditions. ...
(Date:4/18/2017)... DUBLIN, Ohio , April 18, 2017  Cardinal ... its Non-GAAP 1 fiscal 2017 earnings per share ... 2018 and 2019.  This is in conjunction with this ... Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... EPS from continuing operations will be at the bottom ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 28, 2017 , ... Semrock’s highly popular SearchLight Spectra Viewer ... resource for fluorescence microscopists and optical system designers, enabling The Right Solution, Right ... the globe, SearchLight has become a tremendously popular tool for the fluorescence imaging ...
(Date:4/27/2017)... ... April 27, 2017 , ... Healthcare companies are trying to ... rapidly reject an outdated healthcare executive resume. , “If you’re a healthcare executive open ... resume and wondering if it’s as ready as you are for a new job ...
(Date:4/27/2017)... ... 27, 2017 , ... SyncDog, Inc. , the leading ... Live! 2017 in Santa Clara, California. Each year, MobileIron Live! assembles mobility ... organizations maximize the benefits of mobility in their operations securely. MobileIron ...
(Date:4/27/2017)... ... April 27, 2017 , ... Plastic Surgery Associates is ... been asked to present at the upcoming Aesthetic Meeting. Held in San Diego, at ... Drs. Furnas and Canales will lend their expertise to the Premier Global Hot Topics ...
(Date:4/26/2017)... WASHINGTON, DC (PRWEB) , ... ... ... Telemedicine Association (ATA) is thrilled to announce the ATA 2017 President’s Awards ... telehealth innovation and demonstrated superior healthcare delivery. , The ATA 2017 ...
Breaking Medicine News(10 mins):